2019
Aggressive Subsets of Metastatic Triple Negative Breast Cancer
Singh J, Asad S, Zhang Y, Nock W, Adams E, Damicis A, Ramaswamy B, Williams N, Parsons HA, Adalsteinsson VA, Winer EP, Lin NU, Partridge AH, Overmoyer B, Stover DG. Aggressive Subsets of Metastatic Triple Negative Breast Cancer. Clinical Breast Cancer 2019, 20: e20-e26. PMID: 31631016, DOI: 10.1016/j.clbc.2019.06.012.Peer-Reviewed Original ResearchConceptsMetastatic triple-negative breast cancerInflammatory breast cancerTriple-negative breast cancerWorse overall survivalYounger patientsOverall survivalBreast cancerIBC groupMetastatic breast cancer subtypesYounger groupFrequent lung metastasisMedian overall survivalSite of metastasisSingle-institution cohortNegative breast cancerBreast cancer subtypesClinicopathologic characteristicsMetastatic diagnosisMetastatic sitesWorse prognosisLung metastasesPoor prognosisSurvival outcomesPrimary diagnosisAggressive subsetGenomic landscape of de novo stage IV breast cancer.
Garrido-Castro A, Spurr L, Hughes M, Li Y, Cherniack A, Bychkovsky B, Barroso-Sousa R, Di Lascio S, Files J, Kumari P, Cerami E, Krop I, MacConaill L, Lindeman N, Rollins B, Johnson B, Wagle N, Winer E, Dillon D, Lin N. Genomic landscape of de novo stage IV breast cancer. Journal Of Clinical Oncology 2019, 37: 1022-1022. DOI: 10.1200/jco.2019.37.15_suppl.1022.Peer-Reviewed Original ResearchDe novo stage IV breast cancerRecurrent metastatic breast cancerStage IV breast cancerBreast cancerMetastatic tumorsMHC class II expressionMetastatic breast cancerPoor overall survivalClass II expressionFisher's exact testEpithelial-mesenchymal transitionPrimary TNBCCopy number variationsOverall survivalMetastatic sitesCCND1 amplificationImmune escapePotential resistance mechanismsDistinct genomic profilesMetastatic driversMetastatic samplesTreatment selectionExact testMetastatic potentialGenomic profiling
2011
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840
Lichtman S, Hurria A, Cirrincione C, Seidman A, Winer E, Hudis C, Cohen H, Muss H, B F. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Annals Of Oncology 2011, 23: 632-638. PMID: 21693770, PMCID: PMC3331731, DOI: 10.1093/annonc/mdr297.Peer-Reviewed Original ResearchConceptsProgression-free survivalGood performance statusFirst-line therapyMetastatic breast cancerOverall survivalPerformance statusBreast cancerOlder womenLeukemia Group B StudySecond-line therapyImproved overall survivalDoses of paclitaxelEstrogen receptor-positive statusTolerability of paclitaxelToxic effectsBilirubin elevationPaclitaxel efficacyWeekly paclitaxelOlder patientsMetastatic sitesTumor responseSimilar efficacyPositive statusSpecific toxic effectsPatients